ES2180626T3 - Composiciones que comprenden un agente bloqueante de la desgranulacion de celulas cebadas para el tratamiento de estados gastrointestinales dolorosos endogenos de origen no inflamatorio y no ulcerativo. - Google Patents
Composiciones que comprenden un agente bloqueante de la desgranulacion de celulas cebadas para el tratamiento de estados gastrointestinales dolorosos endogenos de origen no inflamatorio y no ulcerativo.Info
- Publication number
- ES2180626T3 ES2180626T3 ES95909451T ES95909451T ES2180626T3 ES 2180626 T3 ES2180626 T3 ES 2180626T3 ES 95909451 T ES95909451 T ES 95909451T ES 95909451 T ES95909451 T ES 95909451T ES 2180626 T3 ES2180626 T3 ES 2180626T3
- Authority
- ES
- Spain
- Prior art keywords
- inflammatory
- painful
- blocking agent
- degranulation
- gastrointestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
SE DESCRIBE UN METODO PARA EL TRATAMIENTO DE ESTADOS GASTROINTESTINALES ENDOGENOS Y DOLOROSOS DE ORIGEN NO INFLAMATORIO Y NO ULCERATIVO, COMO LA MIGRAÑA ABDOMINAL Y EL SINDROME INTESTINAL IRRITATIVO, QUE CONSISTE EN LA ADMINISTRACION DE UNA CANTIDAD FARMACOLOGICAMENTE EFICAZ DE UN AGENTE BLOQUEADOR DE LA DESGRANULACION DE LAS CELULAS CEBADAS, POR EJEMPLO, UNA POLIAMINA NATURAL, UN ANTAGONISTA HETEROCICLICO DEL RECEPTOR DE HISTAMINA TIPO 1, UN AGONISTA DEL RECEPTOR DE HISTAMINA TIPO 3 O UNA HORMONA SEXUAL ANTIFEMENINA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/193,597 US5648355A (en) | 1994-02-09 | 1994-02-09 | Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2180626T3 true ES2180626T3 (es) | 2003-02-16 |
Family
ID=22714282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95909451T Expired - Lifetime ES2180626T3 (es) | 1994-02-09 | 1995-02-09 | Composiciones que comprenden un agente bloqueante de la desgranulacion de celulas cebadas para el tratamiento de estados gastrointestinales dolorosos endogenos de origen no inflamatorio y no ulcerativo. |
Country Status (8)
Country | Link |
---|---|
US (1) | US5648355A (es) |
EP (2) | EP0748217B1 (es) |
AT (1) | ATE221776T1 (es) |
AU (1) | AU1741295A (es) |
CA (1) | CA2183069A1 (es) |
DE (1) | DE69527706T2 (es) |
ES (1) | ES2180626T3 (es) |
WO (1) | WO1995021611A2 (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6562629B1 (en) | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US5888529A (en) * | 1997-03-28 | 1999-03-30 | The Regents Of The University Of California | Ileus treatment method |
US7906153B2 (en) * | 1998-04-08 | 2011-03-15 | Theta Biomedical Consulting & Development Co., Inc. | Anti-inflammatory compositions for treating multiple sclerosis |
US20080153761A1 (en) * | 1998-04-08 | 2008-06-26 | Theoharides Theoharis C | Compositions for protection against superficial vasodilator flush syndrome, and methods of use |
US7799766B2 (en) * | 1998-04-08 | 2010-09-21 | Theta Biomedical Consulting & Development Co., Inc. | Composition for treating hormonally-dependent cancers |
US6689748B1 (en) * | 1998-04-08 | 2004-02-10 | Theoharis C. Theoharides | Method of treating mast cell activation-induced diseases with a proteoglycan |
US6984667B2 (en) * | 1998-04-08 | 2006-01-10 | Theta Biomedical Consulting And Development Co. | Synergistic proteoglycan compositions for inflammatory conditions |
US20050220909A1 (en) * | 2004-03-30 | 2005-10-06 | Theoharides Theoharis C | Composition for protection against superficial vasodilator flush syndrome |
US20040230559A1 (en) * | 1999-08-09 | 2004-11-18 | Mark Newman | Information processing device and information processing method |
US7151102B2 (en) * | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
WO2003013245A1 (en) * | 2001-08-07 | 2003-02-20 | Wisconsin Alumni Research Foundation | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy |
KR20040091014A (ko) * | 2002-02-07 | 2004-10-27 | 위스콘신 얼럼나이 리서어치 화운데이션 | 항암 요법과 병행해서 사용하기 위한 폴리아민 화합물 및조성물 |
JP4500161B2 (ja) * | 2002-04-30 | 2010-07-14 | クドス ファーマシューティカルズ リミテッド | フタラジノン誘導体 |
US20040127512A1 (en) * | 2002-12-30 | 2004-07-01 | Bradley Pharmaceuticals, Inc. | Method of treating symptoms of non-constipated irritable bowel syndrome |
US7449464B2 (en) * | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
US20040266787A1 (en) * | 2003-03-25 | 2004-12-30 | Dr. Reddy's Laboratories Limited | Novel amorphous form of [2-[4-[(4-chlorophenyl)-phenyl methyl]-1-piperazinyl]ethoxy]acetic acid and process for the preparation thereof |
US20050020608A1 (en) * | 2003-03-25 | 2005-01-27 | Dr. Reddy's Laboratories Limited | Crystalline cetirizine monohydrochloride |
DK1624936T3 (da) | 2003-05-16 | 2010-03-15 | Univ Laval | CNS-chloridmodulering og anvendelser deraf |
US20050124965A1 (en) * | 2003-12-08 | 2005-06-09 | Becton, Dickinson And Company | Phosphatase inhibitor sample collection system |
US7923043B2 (en) * | 2004-03-30 | 2011-04-12 | Theta Biomedical Consulting & Development Co., Inc. | Method for protecting humans against superficial vasodilator flush syndrome |
WO2005110490A1 (en) * | 2004-05-14 | 2005-11-24 | Universite Laval | Phospholipase c gamma modulation and uses thereof for management of pain and nociception |
GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
GB0428111D0 (en) * | 2004-12-22 | 2005-01-26 | Kudos Pharm Ltd | Pthalazinone derivatives |
EP1895986A2 (en) * | 2005-05-09 | 2008-03-12 | Azur Pharma | Formulations of mast cell stabilizing agents for delivery to the colon |
GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
US20070286892A1 (en) * | 2006-06-13 | 2007-12-13 | Uri Herzberg | Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals |
CN101484436A (zh) * | 2006-06-15 | 2009-07-15 | 库多斯药物有限公司 | 作为parp抑制剂的2-氧基杂芳基酰胺衍生物 |
JP2009539963A (ja) * | 2006-06-15 | 2009-11-19 | クドス ファーマシューティカルズ リミテッド | Parp阻害剤 |
US20090209520A1 (en) * | 2006-06-15 | 2009-08-20 | Kudos Pharmaceuticals Limited | 2 -oxybenzamide derivatives as parp inhibitors |
TWI404716B (zh) * | 2006-10-17 | 2013-08-11 | Kudos Pharm Ltd | 酞嗪酮(phthalazinone)衍生物 |
TW200838534A (en) | 2007-02-07 | 2008-10-01 | Astellas Pharma Inc | Treatment for irritable bowel syndrome |
US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
TW200900396A (en) * | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
WO2008153761A1 (en) * | 2007-05-23 | 2008-12-18 | Mastcell Pharmaceuticals, Inc. | Methods |
US20090023727A1 (en) * | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
AU2008299721A1 (en) | 2007-09-14 | 2009-03-19 | Astrazeneca Ab | Phthalazinone derivatives |
CN101821242B (zh) * | 2007-10-17 | 2013-07-24 | 库多斯药物有限公司 | 4-[3-(4-环丙烷羰基-哌嗪-1-羰基)-4-氟-苄基]-2h-酞嗪-1-酮 |
UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
WO2009142772A2 (en) | 2008-05-23 | 2009-11-26 | Mastcell Pharmaceuticals, Inc. | Methods and treatment for allergies and inflammation associated with gastrointestinal diseases |
CN102238945B (zh) * | 2008-10-07 | 2014-10-29 | 阿斯利康(英国)有限公司 | 药物制剂514 |
TW201114756A (en) * | 2009-07-15 | 2011-05-01 | Astrazeneca Ab | Phthalazinone compound |
US9176146B2 (en) * | 2009-08-03 | 2015-11-03 | Theta Biomedical Consulting & Development Co., Inc. | Methods of treating autism spectrum disorders and compositions for same |
US9050275B2 (en) * | 2009-08-03 | 2015-06-09 | Theta Biomedical Consulting & Development Co., Inc. | Methods of screening for and treating autism spectrum disorders and compositions for same |
LT3003327T (lt) | 2013-06-05 | 2017-12-27 | Tricida Inc. | Protonus surišantys polimerai, skirti geriamajam vartojimui |
ES2857177T3 (es) | 2014-12-10 | 2021-09-28 | Tricida Inc | Polímeros de unión de protones para administración oral |
US20190209607A1 (en) | 2016-05-06 | 2019-07-11 | Tricida, Inc. | Compositions for treating acid-base disorders |
US11266684B2 (en) | 2017-11-03 | 2022-03-08 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4507321A (en) * | 1982-02-17 | 1985-03-26 | The Research Foundation Of State University Of New York | Epithelial cell growth regulating composition containing polyamines and a method of using same |
FR2630328B1 (fr) * | 1988-04-22 | 1990-08-24 | Inst Nat Sante Rech Med | Derive de l'histamine, sa preparation et son application en therapeutique |
US4843074A (en) * | 1988-05-17 | 1989-06-27 | Marion Laboratories, Inc. | 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts |
NZ235877A (en) * | 1989-11-02 | 1992-09-25 | Mcneil Ppc Inc | Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence |
US5250529A (en) * | 1990-02-08 | 1993-10-05 | Kos Pharmaceuticals, Inc. | Method alleviating migraine headache with mast cell degranulation blocking agents |
US5057322A (en) * | 1990-08-10 | 1991-10-15 | Baker Cummins Dermatologicals, Inc. | Method of treating mast cell disease |
NZ246748A (en) * | 1991-12-27 | 1999-05-28 | Kos Pharma Inc | Migraine-preventing medicaments comprising a mast cell degranulation blocking agent (e.g. hydroxyzine, ketotifen, azatadine, azelastine, cyproheptadine, oxatomide, terfenadine, etc) |
-
1994
- 1994-02-09 US US08/193,597 patent/US5648355A/en not_active Expired - Lifetime
-
1995
- 1995-02-09 AU AU17412/95A patent/AU1741295A/en not_active Abandoned
- 1995-02-09 EP EP95909451A patent/EP0748217B1/en not_active Expired - Lifetime
- 1995-02-09 AT AT95909451T patent/ATE221776T1/de not_active IP Right Cessation
- 1995-02-09 ES ES95909451T patent/ES2180626T3/es not_active Expired - Lifetime
- 1995-02-09 EP EP02075270A patent/EP1203586A3/en not_active Withdrawn
- 1995-02-09 CA CA002183069A patent/CA2183069A1/en not_active Abandoned
- 1995-02-09 WO PCT/US1995/001392 patent/WO1995021611A2/en active IP Right Grant
- 1995-02-09 DE DE69527706T patent/DE69527706T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1203586A3 (en) | 2002-10-30 |
WO1995021611A3 (en) | 1995-10-05 |
DE69527706D1 (de) | 2002-09-12 |
AU1741295A (en) | 1995-08-29 |
EP0748217A1 (en) | 1996-12-18 |
EP0748217B1 (en) | 2002-08-07 |
CA2183069A1 (en) | 1995-08-17 |
US5648355A (en) | 1997-07-15 |
DE69527706T2 (de) | 2002-11-28 |
ATE221776T1 (de) | 2002-08-15 |
WO1995021611A2 (en) | 1995-08-17 |
EP1203586A2 (en) | 2002-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2180626T3 (es) | Composiciones que comprenden un agente bloqueante de la desgranulacion de celulas cebadas para el tratamiento de estados gastrointestinales dolorosos endogenos de origen no inflamatorio y no ulcerativo. | |
ECSP055840A (es) | Derivados de 4 -tetrazolil-4fenilpiperidina para el tratamiento del dolor | |
NO953093D0 (no) | Forbindelser med både sterk kalsiumantagonist- og antioksidantvirkning, samt anvendelse derav som cellebeskyttende midler | |
PE20000129A1 (es) | 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa | |
ES2133270T3 (es) | Terapia de combinacion para la profilaxis y/o el tratamiento de hiperplasia prostatica benigna. | |
TR200100824T2 (tr) | İleumda safra asidi taşınmasının ve taurokolat alımının inhibitörleri olarak aktifliğe sahip benzotiepinler | |
PT735890E (pt) | Misturas de 2',3'-didesoxi-inosina e hidroxicarbamida para inibicao da disseminacao retroviral | |
BR9811099A (pt) | Inibidores de urocinase | |
BR0206644A (pt) | Combinações de inibidor(es) de absorção de esteróis com agente(s) cardiovascular(es) para o tratamento de condições vasculares | |
CY1105254T1 (el) | Θepαπεια του διαβητη με θειαζολιδινδιονη, εκκριταγωγο ινσουλινης και διγουανιδιο | |
GT199700009AA (es) | Terapia combinada para la osteoporosis | |
NO20034012L (no) | Innretning og fremgangsmåte ved dyrehold | |
BR9914901A (pt) | Agonistas do receptor 5ht1 e metoclopramida para o tratamento de enxaqueca | |
KR950010887A (ko) | 연골 퇴화 억제 방법 | |
BR0112212A (pt) | Uma combinação de inibidores de fbpase e agentes antidiabéticos úteis para o tratamento de diabetes | |
ES2150727T3 (es) | Microbicidas. | |
BR9813996A (pt) | 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio | |
KR970061246A (ko) | 테스토스테론을 증가시키기 위한 약학 조성물 | |
NO985116L (no) | Sammensetning som omfatter en KATP kanalhemmer for anvendelse i behandling av hemoragisk sjokk | |
BR9907715A (pt) | Composição oftálmica/método para tratamento de lesão córnea e/ou de estesia córnea deteriordada, sìndrome de olho seco, hipolarcrimação e uso de um inibidor de redutase de aldose | |
ES2187184T3 (es) | Fosfoepoxidos, procedimiento de fabricacion y aplicaciones. | |
BR0011339A (pt) | Composto, uso, e processo para preparar o mesmo, composição farmacêutica, e, método para tratar uma condição de doença mediada por metaloproteinase | |
FI962369A0 (fi) | Farmaseuttinen formulointi myrkytyksen ehkäisemiseksi tai esihoidoksi organofosforisilla koliiniesteraasi-inhibiittoreilla | |
TR200200899T2 (tr) | Endometrioz veya kısırlığın tedavisi ya da doğurganlığın geliştirilmesi. | |
BR9810292A (pt) | Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e inibidor de alfa-glicosidase |